Navana Pharmaceuticals PLC (DSE:NAVANAPHAR)
Bangladesh
· Delayed Price · Currency is BDT 56.20
+1.30 (2.37%)
At close: Mar 9, 2026
Navana Pharmaceuticals Revenue
Navana Pharmaceuticals had revenue of 2.81B BDT in the quarter ending September 30, 2025, with 31.69% growth. This brings the company's revenue in the last twelve months to 9.52B, up 28.58% year-over-year. In the fiscal year ending June 30, 2025, Navana Pharmaceuticals had annual revenue of 8.84B with 28.19% growth.
Revenue (ttm)
9.52B
Revenue Growth
+28.58%
P/S Ratio
0.63
Revenue / Employee
1.98M
Employees
4,798
Market Cap
6.04B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Orion Pharma | 3.12B |
| Asiatic Laboratories | 2.24B |
| Techno Drugs | 3.15B |
| The IBN SINA Pharmaceutical Industry | 13.42B |
| The ACME Laboratories | 38.86B |
| Ambee Pharmaceuticals | 193.90M |
| Pharma Aids | 453.49M |
| Beacon Pharmaceuticals | 11.58B |